Global Pharma Market Reviewed & Forecast in New Cutting-Edge MP Advisors Report Available at MarketPublishers.com16 Jan 2013 • by Natalie Aster
LONDON – Having weathered the recent economic recession, the global pharma market is currently in the recovery period. Some of the shining opportunities offered by the market include deconsolidation, discipline in M&A, new drug approvals that will change the standard of care in some therapy areas, outcome studies aimed at transforming market potential of drugs. However, healthcare spending pressures as well as investigational studies in high risk therapy area could pose a challenge to the sector growth.
Followed by European nations and Japan, the USA is the most influential pharma market, and is anticipated to reach almost USD 400 billion in value by end-2014. Asia and Latin America’s pharma markets continue their upward trajectory, supported by factors like increasing healthcare spending, as well as high rates of disease incidence and prevalence in those geographies, among others.
New market research report “Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma” worked out by MP Advisors offers a comprehensive guide to the global pharmaсeutical market. The study provides an in-depth assessment of individual large caps, discusses promising late-stage pipeline drugs, forecasts key marketed drugs, and reviews the potential impact of some essential oncoming milestones on the pharma industry worldwide. The prevalence, market size opportunities and competitive landscape analysis of the major therapy areas expected to shape up the big pharma business moving forward are among the hot issues talked about in the report as well. The research is supplemented with a detailed analysis of the future prospects for the market.
Top companies discussed in the study include: AstraZeneca, Bristol Myers-Squibb, Pfizer, Merck, Novartis, Novo Nordisk, GlaxoSmithKline, Roche, Sanofi and Eli-Lilly.
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma
Published: January, 2013
Price: US$ 2,500.00
More Global Pharmaceutical & Biotechnology Outlook Reports by MP Advisors Include:
- Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma
- Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech
- Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars
More new market research reports by the publisher can be found at MP Advisors page.